AO
Therapeutic Areas
Vor Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Telitacicept | Myasthenia Gravis (MG) | Phase 3 |
Leadership Team at Vor Biopharma
JK
Jean-Paul Kress, MD
Chief Executive Officer and Chairman
SM
Sandy Mahatme
Chief Financial Officer, Chief Business Officer
JS
Jeremy Sokolove, MD
Chief Medical Officer
DM
Dallan Murray
Chief Commercial Officer
NZ
Navid Z. Khan, PhD
Chief Medical Affairs Officer
CL
Carol Lincoln, CCP
Head of Human Resources
AL
Andrew Levin, M.D., Ph.D.
Board of Directors (RA Capital)
WJ
Wouter Joustra
Board of Directors (Forbion)